Clinical Trial Update: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study of Lu-177 DOTATATE for glioblastoma evaluating combination with standard of care in newly diagnosed disease and as a single agent i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Lutetium-177 DOTATATE (177Lu-DOTA-TATE) (Lutetium-177 DOTATATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING